Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Geoffrey I Shapiro

Abstract

Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (cdks) to reach clinical trial. In the majority of solid tumor cell lines and xenografts, flavopiridol induces cell cycle arrest and tumor growth inhibition. This is reflected in clinical outcomes: across multiple Phase II trials there are subsets of patients with prolonged stable disease, although few responses have been observed. Flavopiridol displays sequence-dependent cytotoxic synergy with chemotherapy agents. These effects are most marked when chemotherapy precedes flavopiridol. In the case of DNA-damaging agents that impose S-phase delay, flavopiridol-mediated cdk inhibition disrupts the phosphorylation of E2F-1, leading to inappropriate persistence of its activity, inducing apoptotic pathways. This mechanism has been exploited in a Phase I trial of sequential gemcitabine and flavopiridol that has produced promising results. Flavopiridol is also synergistic with taxanes. Inhibition of cyclin B-cdk1 by flavopiridol accelerates exit from an abnormal mitosis associated with taxane-induced cell death and reduces the phosphorylation of survivin, preventing its stabilization and the cellular protection it affords after taxane exposure. The sequential combin...Continue Reading

References

May 15, 1995·Genes & Development·C J Sherr, J M Roberts
Nov 18, 1994·Cell·C J Sherr
Aug 1, 1994·Genes & Development·B D DynlachtE Harlow
Jun 15, 1994·Biochemical and Biophysical Research Communications·M D LosiewiczP J Worland
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·W F De AzevedoS H Kim
Dec 6, 1996·Science·C J Sherr
May 9, 1997·The Journal of Biological Chemistry·T Zarkowska, S Mittnacht
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SenderowiczE A Sausville
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y N ChenW G Kaelin
Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts
Dec 22, 1999·The Journal of Clinical Investigation·G I Shapiro, J W Harper
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M StadlerE E Vokes
Mar 4, 2000·Journal of the National Cancer Institute·A M Senderowicz, E A Sausville
Jul 25, 2000·The Journal of Biological Chemistry·S H ChaoD H Price
Nov 4, 2000·Expert Opinion on Investigational Drugs·S ManiR Pestell
Apr 20, 2001·Critical Reviews in Oncology/hematology·H H Sedlacek
Jun 30, 2001·The Journal of Biological Chemistry·S H Chao, D H Price
Apr 3, 2002·Trends in Molecular Medicine·Edward A Sausville
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary K SchwartzDavid Kelsen
Aug 2, 2002·Cancer Cell·Daniel S O'ConnorDario C Altieri
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoinette R TanAdrian M Senderowicz
Nov 27, 2002·Cancer Chemotherapy and Pharmacology·James P ThomasGeorge Wilding
Apr 5, 2003·Cancer Cell·Osamu Tetsu, Frank McCormick
Aug 19, 2003·Nature Genetics·Sagrario OrtegaMariano Barbacid
Aug 28, 2003·Cell·Yan GengPiotr Sicinski

❮ Previous
Next ❯

Citations

May 30, 2008·Cancer Chemotherapy and Pharmacology·Cornel J PhillipVarsha Gandhi
Oct 26, 2005·Current Treatment Options in Oncology·Nancy R McAllister, Stephen L Lessnick
Oct 17, 2013·The International Journal of Biochemistry & Cell Biology·Divyashree RavishankarHelen M I Osborn
Mar 23, 2005·Bioorganic & Medicinal Chemistry Letters·Chafiq HamdouchiHarold B Brooks
Jan 31, 2013·Journal of Natural Products·Maoquan ZhouJon S Thorson
Apr 25, 2008·Molecular Biology of the Cell·Sergiy I Borysov, Thomas M Guadagno
Jul 28, 2006·Cold Spring Harbor Symposia on Quantitative Biology·L A GarrawayW R Sellers
Jan 22, 2011·Sarcoma·Rachel ConyersDavid M Thomas
Mar 31, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beata HolkovaSteven Grant
Jan 10, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jia JiMitch A Phelps
Sep 3, 2009·Cancer Prevention Research·Amelie BoquoiGreg H Enders
Nov 11, 2008·Journal of Translational Medicine·Astrid RohrbeckUlrich-Peter Rohr
Nov 19, 2010·Journal of Experimental & Clinical Cancer Research : CR·Ling GuZhigui Ma
Apr 13, 2011·PLoS Neglected Tropical Diseases·Roderick G WalkerJeremy C Mottram
Dec 1, 2009·Future Medicinal Chemistry·Józefa Węsierska-GądekVladimír Kryštof
May 29, 2010·Cellular and Molecular Life Sciences : CMLS·Guillaume JacqueminOlivier Micheau
Mar 11, 2005·Expert Review of Anticancer Therapy·Heather WakeleeChandra P Belani
Apr 15, 2006·Expert Review of Anticancer Therapy·Harriet Wikman, Eeva Kettunen
Dec 24, 2005·Expert Opinion on Investigational Drugs·Józefa Wesierska-Gadek, Gerald Schmid
Mar 13, 2009·Expert Opinion on Investigational Drugs·M Wasif SaifAlan J Husband
Oct 25, 2011·Expert Opinion on Investigational Drugs·Józefa Węsierska-Gądek, Matthias P Kramer
May 9, 2012·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yuxin XuXingyuan Ma
Aug 23, 2011·Clinical Colorectal Cancer·Jonathan M HernandezDavid Shibata
Apr 28, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Paul DentSteven Grant
Oct 10, 2007·Clinical Lung Cancer·Hidefumi SasakiYoshitaka Fujii
Jul 22, 2008·International Journal of Radiation Oncology, Biology, Physics·Takamitsu HaraTomio Inoue
Mar 22, 2008·Neurobiology of Disease·Filippo CaraciAgata Copani
Jan 22, 2008·Cancer Treatment Reviews·J K AdamskiG W J Makin
Jan 29, 2008·Biochimica Et Biophysica Acta·Axel HuberWalee Chamulitrat
Sep 11, 2007·Cancer Treatment Reviews·Daniela D RosaAhmad Awada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.